Glimepiride blocks potassium channels on pancreatic β-cells causing insulin release and also improves sensitivity of insulin receptors, reducing insulin resistance and improving blood glucose control.
Glimepiride 1 mg
One tablet once daily.
Dizziness, headache, nausea.
Hypersensitivity to Glimepiride.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Glimepiride stimulates biphasic insulin release similar to the natural insulin pattern and reduces chances of hypoglycemia while improving insulin sensitivity.
Glimepiride 2 mg
One tablet once daily.
Dizziness, headache, nausea.
Hypersensitivity to Glimepiride.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Combination of Glimepiride and Metformin improves insulin release, reduces insulin resistance, improves triglyceride profile and enhances glycemic control with once-daily dosage.
Glimepiride 1 mg + Metformin (SR) 500 mg
One tablet once daily.
Dizziness, weakness, headache, nausea, hypoglycemia.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Dual therapy combining Glimepiride and Metformin to enhance insulin release and reduce insulin resistance for improved glycemic control and reduced cardiovascular risk.
Glimepiride 2 mg + Metformin (SR) 500 mg
One tablet once daily.
Dizziness, weakness, headache, nausea, hypoglycemia.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
“For Healthcare Professionals & Business Partners Only”
Combination of Glimepiride and sustained-release Metformin designed for patients requiring stronger glycemic control with reduction in postprandial glucose and triglycerides.
Glimepiride 3 mg + Metformin (SR) 850 mg
One tablet once daily.
Dizziness, weakness, headache, nausea, hypoglycemia.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Gliclazide offers better glucose control with fewer hypoglycemic events, lower secondary failure rates and antioxidant benefits improving vascular protection.
Gliclazide 80 mg
40–80 mg/day before meal; max 320 mg/day.
IDDM, pregnancy, severe renal/hepatic impairment.
Hypoglycemia, GI upset, headache, dizziness, skin rash.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Dual therapy that improves insulin secretion and decreases insulin resistance for patients not controlled with single agent therapy.
Glimepiride 1 mg + Metformin (SR) 1000 mg
Lactic acidosis (rare), nausea, vomiting, diarrhea, abdominal pain.
Hypersensitivity, renal impairment, liver damage.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Dual mechanism combination therapy improving glycemic control in patients inadequately managed with monotherapy.
Glimepiride 2 mg + Metformin (SR) 1000 mg
Lactic acidosis (rare), nausea, vomiting, diarrhea, abdominal discomfort.
Hypersensitivity, renal impairment, liver damage.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Enhanced dose Metformin SR + Glimepiride formulation designed for tougher cases requiring stronger glycemic response.
Glimepiride 3 mg + Metformin SR 1000 mg
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Higher strength Glimepiride + Metformin SR therapy for uncontrolled diabetic patients requiring stronger management.
Glimepiride 4 mg + Metformin SR 1000 mg
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Metformin SR 500 mg + Glimepiride 0.5 mg
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Metformin SR 500 mg + Gliclazide 80 mg + Voglibose 0.2 mg
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Metformin SR 500 mg + Gliclazide 80 mg + Voglibose 0.3 mg
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Company Identification Number
( CIN ) : U24230MH1975PLC018296
Medley House, D2,
M.I.D.C. Area,
Andheri (East),
Mumbai-400 093, INDIA